查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1468402

体内CRO 市场报告按类型（囓齿动物、非囓齿动物）、GLP 类型（非GLP、GLP 毒理学）、适应症（自体免疫/发炎状况、疼痛管理、肿瘤、中枢神经系统状况、糖尿病、肥胖等） 、及地区 2024-2032

In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球体内CRO市场规模达到49亿美元。

体内合约研究组织（CRO）是在合约基础上进行广泛的生物製药研究的机构。他们透过提供外包服务支援製药和生物技术公司开发有效的药物、疫苗和医疗器材。与体外CRO相比，体内CRO涉及在活体生物体中进行的研究，并进行人体临床试验以评估药物的安全性和有效性，而不是对移除的细胞和组织进行检查。它们有助于研究机构管理复杂的医学测试，以最低的成本开发有效的药物，并透过避免招聘、筹款和临床准备造成的延误来优化工作流程。因此，体内 CRO 在疼痛管理、肿瘤学以及中枢神经系统 (CNS) 损伤和其他疾病的治疗中已广泛应用。目前，它们分为囓齿动物和非囓齿动物类型。

体内 CRO 市场趋势：

各种心血管疾病的盛行率不断增加，特别是在老年族群中，以及对有效药物和基于肿瘤学的新型诊断和治疗疗法的需求不断增长，主要推动了市场的成长。此外，合约研究、开发和製造组织 (CRDMO) 对临床规模生产活性药物成分 (API) 的需求不断增长，以及对生物相似药而非单株抗体的倾向的转变，也是其他成长诱导因素。此外，日益严重的健康问题促使生技公司与 CRO 合作设计有效的新型疫苗，特别是在 COVID-19 大流行期间，这有助于市场成长。此外，在临床前活动期间广泛利用体内 CRO 进行毒理学和药物动力学研究正在推动市场成长。除此之外，生物等效性的出现、仿製药的快速增长、持续的专利到期以及设计个人化药物的持续研发 (R&D) 活动正在为市场创造积极的前景。

本报告回答的关键问题

  • 2023年全球体内CRO市场规模有多大？
  • 2024-2032年全球体内CRO市场的预期成长率是多少？
  • 推动全球体内CRO市场的关键因素是什么？
  • COVID-19 对全球体内 CRO 市场有何影响？
  • 全球体内 CRO 市场按类型划分是怎样的？
  • 基于GLP类型的全球体内CRO市场的细分如何？
  • 根据适应症，全球体内 CRO 市场的细分如何？
  • 全球体内CRO市场的关键区域有哪些？
  • 全球体内 CRO 市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球体内 CRO 市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 囓齿动物
    • 市场走向
    • 关键环节
      • 老鼠
      • 老鼠
      • 其他的
    • 市场预测
  • 不囓齿动物
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依 GLP 类型

  • 非GLP
    • 市场走向
    • 关键环节
      • 内部
      • 外包
    • 市场预测
  • GLP毒理学
    • 市场走向
    • 关键环节
      • 内部
      • 外包
    • 市场预测

第 8 章：市场区隔：依迹象

  • 自体免疫/发炎状况
    • 市场走向
    • 关键环节
      • 类风湿关节炎
      • 多发性硬化症
      • 骨关节炎
      • 急躁性肠症候群
      • 其他的
    • 市场预测
  • 疼痛管理
    • 市场走向
    • 关键环节
      • 慢性疼痛
      • 急性疼痛
    • 市场预测
  • 肿瘤学
    • 市场走向
    • 关键环节
      • 血癌
      • 实体肿瘤
      • 其他的
    • 市场预测
  • 中枢神经系统疾病
    • 市场走向
    • 关键环节
      • 癫痫
      • 帕金森氏症
      • 亨丁顿舞蹈症
      • 中风
      • 创伤性脑损伤
      • 肌萎缩侧索硬化症
      • 肌肉再生
      • 其他的
    • 市场预测
  • 糖尿病
    • 市场走向
    • 市场预测
  • 肥胖
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Charles River Laboratories International Inc.
    • Evotec SE
    • ICON plc
    • Iris Pharma (ABIONYX Pharma)
    • Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • North American Science Associates LLC
    • Parexel International Corporation
    • Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
    • Pronexus Analytical AB
    • Syneos Health
    • WuXi AppTec
Product Code: SR112024A6267

The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.

In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.

In-vivo CRO Market Trends:

The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.

Breakup by Type:

Rodent

Rats

Mice

Others

Non-Rodent

Breakup by GLP Type:

Non-GLP

In House

Outsourcing

GLP Toxicology

In House

Outsourcing

Breakup by Indication:

Autoimmune/Inflammation Conditions

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumor

Others

CNS Conditions

Epilepsy

Parkinson's Disease

Huntington's Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Diabetes

Obesity

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.

Key Questions Answered in This Report

  • 1. What was the size of the global in-vivo CRO market in 2023?
  • 2. What is the expected growth rate of the global in-vivo CRO market during 2024-2032?
  • 3. What are the key factors driving the global in-vivo CRO market?
  • 4. What has been the impact of COVID-19 on the global in-vivo CRO market?
  • 5. What is the breakup of the global in-vivo CRO market based on the type?
  • 6. What is the breakup of the global in-vivo CRO market based on the GLP type?
  • 7. What is the breakup of the global in-vivo CRO market based on indication?
  • 8. What are the key regions in the global in-vivo CRO market?
  • 9. Who are the key players/companies in the global in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Rodent
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Rats
      • 6.1.2.2 Mice
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-Rodent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

  • 7.1 Non-GLP
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 In House
      • 7.1.2.2 Outsourcing
    • 7.1.3 Market Forecast
  • 7.2 GLP Toxicology
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 In House
      • 7.2.2.2 Outsourcing
    • 7.2.3 Market Forecast

8 Market Breakup by Indication

  • 8.1 Autoimmune/Inflammation Conditions
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Rheumatoid Arthritis
      • 8.1.2.2 Multiple Sclerosis
      • 8.1.2.3 Osteoarthritis
      • 8.1.2.4 Irritable Bowel Syndrome
      • 8.1.2.5 Others
    • 8.1.3 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Key Segments
      • 8.2.2.1 Chronic Pain
      • 8.2.2.2 Acute Pain
    • 8.2.3 Market Forecast
  • 8.3 Oncology
    • 8.3.1 Market Trends
    • 8.3.2 Key Segments
      • 8.3.2.1 Blood Cancer
      • 8.3.2.2 Solid Tumor
      • 8.3.2.3 Others
    • 8.3.3 Market Forecast
  • 8.4 CNS Conditions
    • 8.4.1 Market Trends
    • 8.4.2 Key Segments
      • 8.4.2.1 Epilepsy
      • 8.4.2.2 Parkinson's Disease
      • 8.4.2.3 Huntington's Disease
      • 8.4.2.4 Stroke
      • 8.4.2.5 Traumatic Brain Injury
      • 8.4.2.6 ALS
      • 8.4.2.7 Muscle Regeneration
      • 8.4.2.8 Others
    • 8.4.3 Market Forecast
  • 8.5 Diabetes
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Obesity
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Charles River Laboratories International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Evotec SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 ICON plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Iris Pharma (ABIONYX Pharma)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 North American Science Associates LLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Parexel International Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Pronexus Analytical AB
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Syneos Health
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: In-vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2023
  • Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2023
  • Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2023
  • Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
  • Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
  • Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vivo CRO Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: In-vivo CRO Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: In-vivo CRO Market Forecast: Breakup by GLP Type (in Million US$), 2024-2032
  • Table 4: Global: In-vivo CRO Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: In-vivo CRO Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: In-vivo CRO Market: Competitive Structure
  • Table 7: Global: In-vivo CRO Market: Key Players